Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
Want to see TVRD full AI Analyst Report?
TVRD Stock Chart & Stats
$3.39
--
Market closed
$3.39
--
Day’s Range― - ―
52-Week Range$2.48 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.55K
Market Cap
$24.67M
Enterprise Value$4.53M
Total Cash (Recent Filing)$30.81M
Total Debt (Recent Filing)$201.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 13, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue1.76
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$8.67Price Target Upside155.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused STAT3 R&D PipelineTvardi’s dedicated focus on STAT3 small-molecule therapeutics creates a clear scientific niche and concentrated R&D strategy. A targeted program can produce differentiated clinical candidates, attract partnerships or licensing, and efficiently allocate limited resources across core assets.
Low Leverage In 2025Very low reported debt in 2025 materially reduces near-term solvency and interest burden risks. That stronger capital structure provides greater flexibility to fund R&D activities without immediate refinancing pressure and supports operational continuity while clinical programs advance.
Improving Cash Burn And Smaller 2025 LossThe marked reduction in cash burn and a smaller 2025 loss indicate improving cost discipline or program prioritization. If sustained, this trend extends runway, lowers near-term financing needs, and increases the likelihood management can advance key assets without repeated dilutive raises.
Bears Say
Zero Revenue In 2025The absence of product revenue eliminates internally generated funding for operations and R&D, forcing reliance on external capital or partnerships. This undermines long-term predictability, increases execution risk for clinical programs, and limits options to scale beyond development.
Persistent Negative Cash Flow And High BurnChronic negative operating and free cash flow depletes reserves and necessitates frequent financing, which can be dilutive or restrictive. Sustained high burn constrains strategic flexibility, delays programs if funding gaps arise, and raises long-term viability concerns absent new revenue or capital.
Past Capital Erosion And Financing DependenceA history of negative equity implies prior recapitalizations and investor dilution, signaling reliance on external funding. This pattern elevates financing risk, can weaken stakeholder confidence, and complicates long-term planning for clinical development and commercialization paths.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $2.48 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $24.67M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 53 days.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics operates as an advanced biopharmaceutical company, specializing in the creation of innovative, orally delivered small molecule treatments. These therapies are designed to modulate the STAT3 pathway, with the objective of tackling fibrosis-related illnesses that currently suffer from a substantial lack of effective medical solutions. Their flagship compound, TTI-101, is presently progressing through Phase 2 clinical studies for its potential in treating both idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
TVRD Stock 12 Month Forecast
Average Price Target
$8.67
▲(155.65% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
8.15% Insiders
7.92% Mutual Funds
11.87% Other Institutional Investors
65.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---